MDACC Study No:2011-1097 ( NCT No: NCT01496313)
Title:An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease
Principal Investigator:Mimi Hu
Treatment Agent:Vandetanib
Study Status:Closed
Study Description:The goal of this clinical research study is to compare how effective 2
different doses of vandetanib may be in helping to control medullary thyroid
cancer. The safety of these doses will also be studied. The study will also
measure levels of drug in the blood (pharmacokinetic [PK] testing).

Vandetanib is FDA approved for the treatment of medullary thyroid cancer. It
is designed to slow the formation of blood vessels in tumors, which may slow
tumor growth.
Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase IV
Treatment Agents:Vandetanib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:AstraZeneca
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Mimi Hu
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-792-2841
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults